Table 1.
Baseline characteristics by pre-trial insulin regimen
| Pre-trial insulin regimen | Premixed insulin | Basal insulin | ||
|---|---|---|---|---|
| Trial insulin regimen | IDegLira | Degludec | IDegLira | Degludec |
| Full analysis set | 39a | 38b | 66 | 67 |
| Age, years | 60.2 (10.7) | 59.7 (8.7) | 54.4 (9.7) | 53.2 (9.9) |
| Duration of diabetes, years | 17.5 (7.8) | 16.5 (7.5) | 12.5 (7.2) | 12.2 (7.0) |
| Daily dose of pre-trial insulin, U | 14.1 (3.4) | 15.6 (2.6) | 15.2 (2.9) | 15.9 (3.0) |
| Male, % | 69.2 | 50.0 | 65.2 | 65.7 |
| Body weight, kg | 71.9 (11.3) | 71.5 (13.4) | 75.1 (12.1) | 77.8 (13.9) |
| BMI, kg/m2 | 26.5 (2.7) | 27.5 (4.5) | 27.7 (3.3) | 28.4 (4.3) |
| FPG, mmol/L | 9.5 (2.7) | 8.8 (3.0) | 8.6 (2.5) | 8.5 (2.2) |
| FPG, mg/dL | 171.9 (48.9) | 159.3 (53.8) | 155.1 (45.0) | 153.5 (40.1) |
| HbA1c, mmol/mol | 66.8 (8.0) | 67.6 (7.4) | 72.8 (10.0) | 71.4 (9.1) |
| HbA1c, % | 8.3 (0.7) | 8.3 (0.7) | 8.8 (0.9) | 8.7 (0.8) |
Full analysis set. Data are mean (SD) values
BMI body mass index, degludec insulin degludec, FPG fasting plasma glucose, HbA1c glycated hemoglobin, IDegLira insulin degludec/liraglutide, SD standard deviation, U unit
aSeven of the 39 patients in the premixed subgroup were receiving insulin degludec/insulin aspart
bNine of the 38 patients in the premixed subgroup were receiving insulin degludec/insulin aspart